

Abstract

Disclosed in the present invention is a class of completely-new HPK1 inhibitory active compounds. In the present invention, the intrinsic mechanistic link of HPK1 kinase to viral
5 infection is explained for the first time. The compounds of the present invention are useful in the treatment of interferon-related diseases, particularly viral infections. Further, provided in the present invention is a method for treating interferon-related diseases using the compounds of the present invention.

10 No figure.